Olivera Finn

This phase 1/2 trial is testing a vaccine made from a piece of the MUC1 protein, which is found on many lung cancer cells. The vaccine is mixed with an adjuvant called Poly-ICLC to boost the immune response. Thirty patients with early or locally advanced non-small cell lung cance…